{"id":1002700,"date":"2026-09-10T16:01:01","date_gmt":"2026-09-10T20:01:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/"},"modified":"2026-09-10T16:01:01","modified_gmt":"2026-09-10T20:01:01","slug":"investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/","title":{"rendered":"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\">NEW YORK<\/span>, <span class=\"legendSpanClass\">Sept. 10, 2026<\/span> \/PRNewswire\/ &#8212; Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against the officers and directors of\u00a0Aardvark Therapeutics, Inc. (NASDAQ: AARD):<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <img decoding=\"async\" src=\"https:\/\/mmx.prnewswire.com\/media\/MS823123\/MooreKuehn.jpg?id=OA2942154\" title=\"logo\" alt=\"logo\" \/>\n        <\/p>\n<\/p><\/div>\n<ul type=\"disc\">\n<li>\n          <b>Aardvark Therapeutics, Inc. (NASDAQ: AARD) <\/b>shareholders should email <a href=\"mailto:fletcher@fmoorelaw.com\" target=\"_blank\" rel=\"nofollow\">fletcher@fmoorelaw.com<\/a><\/li>\n<\/ul>\n<p>\n        <b><br \/>\n          <u>What is the Investigation About<\/u><br \/>\n        <\/b><br \/>\n        <b>?<\/b>\n      <\/p>\n<p>Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases. It is <span>alleged<\/span> that the company, or certain of its officers, overstated the safety and clinical prospects of its lead drug candidate, ARD-101, including by representing that the drug had minimal systemic exposure and had resulted in no serious adverse events.<\/p>\n<p>On February 27, 2026, Aardvark announced that it was pausing its Phase 3 HERO trial after cardiac observations were identified during a healthy-volunteer study. Its stock price subsequently fell $7.02 per share, or approximately 56.2%, to close at $5.47 per share on March 2, 2026. On May 14, 2026, the company announced that the FDA had placed a full clinical hold on ARD-101. Its stock fell an additional $2.16 per share, or approximately 32.1%, to close at $4.57 per share on May 15, 2026.<\/p>\n<p>If you own <b>Aardvark Therapeutics, Inc. (NASDAQ: AARD) <\/b>please contact\u00a0Fletcher Moore at <a href=\"mailto:fletcher@fmoorelaw.com\" target=\"_blank\" rel=\"nofollow\">fletcher@fmoorelaw.com<\/a>.<\/p>\n<p>You may be able to seek monetary damages, corporate governance reforms, reimbursement to the company, and a court-approved incentive award at no cost to you whatsoever.\u00a0 <b><i>All representation is on a contingency fee basis. Shareholders pay no fees or expenses.<\/i><\/b><\/p>\n<p>MOORE LAW PLLC<br \/>30 Wall Street, 8<sup>th<\/sup> Floor<br \/>New York, NY 10005<br \/><a href=\"mailto:fletcher@fmoorelaw.com\" target=\"_blank\" rel=\"nofollow\">fletcher@fmoorelaw.com<\/a><br \/><a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4771799-1&amp;h=2639022391&amp;u=https%3A%2F%2Fwww.fmoorelaw.com&amp;a=www.fmoorelaw.com\" target=\"_blank\" rel=\"nofollow\">www.fmoorelaw.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=NY45390&amp;sd=2026-09-10\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm-302875742.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm-302875742.html<\/a><\/p>\n<p>SOURCE Moore Law PLLC<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY45390&amp;Transmission_Id=202609101557PR_NEWS_USPR_____NY45390&amp;DateId=20260910\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK, Sept. 10, 2026 \/PRNewswire\/ &#8212; Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against the officers and directors of\u00a0Aardvark Therapeutics, Inc. (NASDAQ: AARD): Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders should email fletcher@fmoorelaw.com What is the Investigation About ? Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases. It is alleged that the company, or certain of its officers, overstated the safety and clinical prospects of its lead drug candidate, ARD-101, including by representing that the drug had minimal systemic exposure and had resulted in no serious adverse events. On February 27, 2026, Aardvark announced that it was pausing its Phase 3 HERO trial after cardiac &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1002700","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Sept. 10, 2026 \/PRNewswire\/ &#8212; Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against the officers and directors of\u00a0Aardvark Therapeutics, Inc. (NASDAQ: AARD): Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders should email fletcher@fmoorelaw.com What is the Investigation About ? Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases. It is alleged that the company, or certain of its officers, overstated the safety and clinical prospects of its lead drug candidate, ARD-101, including by representing that the drug had minimal systemic exposure and had resulted in no serious adverse events. On February 27, 2026, Aardvark announced that it was pausing its Phase 3 HERO trial after cardiac &hellip; Continue reading &quot;INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-10T20:01:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS823123\/MooreKuehn.jpg?id=OA2942154\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm\",\"datePublished\":\"2026-09-10T20:01:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\\\/\"},\"wordCount\":277,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS823123\\\/MooreKuehn.jpg?id=OA2942154\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\\\/\",\"name\":\"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS823123\\\/MooreKuehn.jpg?id=OA2942154\",\"datePublished\":\"2026-09-10T20:01:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS823123\\\/MooreKuehn.jpg?id=OA2942154\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS823123\\\/MooreKuehn.jpg?id=OA2942154\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/","og_locale":"en_US","og_type":"article","og_title":"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm - Market Newsdesk","og_description":"PR Newswire NEW YORK, Sept. 10, 2026 \/PRNewswire\/ &#8212; Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against the officers and directors of\u00a0Aardvark Therapeutics, Inc. (NASDAQ: AARD): Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders should email fletcher@fmoorelaw.com What is the Investigation About ? Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases. It is alleged that the company, or certain of its officers, overstated the safety and clinical prospects of its lead drug candidate, ARD-101, including by representing that the drug had minimal systemic exposure and had resulted in no serious adverse events. On February 27, 2026, Aardvark announced that it was pausing its Phase 3 HERO trial after cardiac &hellip; Continue reading \"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-10T20:01:01+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS823123\/MooreKuehn.jpg?id=OA2942154","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm","datePublished":"2026-09-10T20:01:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/"},"wordCount":277,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS823123\/MooreKuehn.jpg?id=OA2942154","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/","name":"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS823123\/MooreKuehn.jpg?id=OA2942154","datePublished":"2026-09-10T20:01:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS823123\/MooreKuehn.jpg?id=OA2942154","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS823123\/MooreKuehn.jpg?id=OA2942154"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investor-action-notice-moore-law-pllc-encourages-investors-in-aardvark-therapeutics-inc-aard-to-contact-law-firm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1002700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1002700"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1002700\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1002700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1002700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1002700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}